Objectives: We sought to assess the efficacy and safety of thrombolytic therapy in patients
with an acute pulmonary embolism (PE). Background: Thrombolytic therapy is approved for …

Background—Randomized trials and meta-analyses have reached conflicting conclusions
about the role of thrombolytic therapy for the treatment of acute pulmonary embolism …

Background In patients with acute pulmonary embolism, thrombolysis results in a more rapid
resolution of pulmonary emboli than heparin treatment. Whether this advantage results in an …

Pulmonary embolism is a prevalent condition that may account for> 300,000 deaths
annually in the United States alone. Although thrombolytics have been studied as a …

Aim Thrombolytic therapy induces faster clot dissolution than anticoagulation in patients with
acute pulmonary embolism (PE) but is associated with an increased risk of haemorrhage …

Pulmonary embolism (PE) is a common disorder that is accompanied by significant
morbidity and mortality. Although anticoagulation is the standard treatment for PE …

Background Thrombolytic therapy is usually reserved for patients with clinically serious or
massive pulmonary embolism (PE). Evidence suggests that thrombolytic agents may …

Background Thrombolytic therapy is usually reserved for people with clinically serious or
massive pulmonary embolism (PE). Evidence suggests that thrombolytic agents may …

OBJECTIVES: To determine whether thrombolytic therapy reduces the rate of death or
complications in patients with acute pulmonary embolism and whether a particular …

Patients with high-risk pulmonary embolism (PE), ie those with shock or hypotension at
presentation, are at high risk of in-hospital death, particularly during the first hours after …